Dimension Therapeutics Expands Its Board Of Directors With The Elections Of Industry Leaders Dr. Georges Gemayel And Arlene M. Morris

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dimension Therapeutics, Inc. (“Dimension” or the “Company”), a leading rare disease company advancing novel, liver-directed treatments for diverse genetic disorders, today announced that it has expanded its Board of Directors with the elections of Georges Gemayel, Ph.D., former Executive Vice President of Genzyme Corporation, and Arlene M. Morris, former CEO of Syndax Pharmaceuticals. Dimension also announced that Donald J. Hayden, Jr., is leaving his position as a member of the Company’s Board of Directors.

Help employers find you! Check out all the jobs and post your resume.